$ATYR
aTyr Pharma Inc

2020 Q3 Form 10-Q Financial Statement

#000156459020053928 Filed on November 13, 2020

View on sec.gov

Income Statement

Concept 2020 Q3 2019 Q3 2019 Q2
Revenue $148.0K $184.0K $94.00K
YoY Change -19.57%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.040M $1.880M $2.420M
YoY Change 8.51% -24.19% -30.46%
% of Gross Profit
Research & Development $4.616M $3.799M $3.314M
YoY Change 21.51% -9.59% -48.89%
% of Gross Profit
Depreciation & Amortization $130.0K $160.0K $150.0K
YoY Change -18.75% -15.79% -25.0%
% of Gross Profit
Operating Expenses $6.660M $5.682M $5.735M
YoY Change 17.21% -14.9% -42.42%
Operating Profit -$6.512M -$5.498M -$5.641M
YoY Change 18.44% -17.66%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net -$88.00K -$147.0K -$207.0K
YoY Change -40.14% -66.36% -54.2%
Pretax Income -$6.600M -$5.650M -$5.850M
YoY Change 16.81% -20.53% -43.8%
Income Tax
% Of Pretax Income
Net Earnings -$6.599M -$5.645M -$5.848M
YoY Change 16.9% -20.65% -43.83%
Net Earnings / Revenue -4458.78% -3067.93% -6221.28%
Basic Earnings Per Share
Diluted Earnings Per Share -$683.9K -$1.468M -$1.806M
COMMON SHARES
Basic Shares Outstanding 3.890M
Diluted Shares Outstanding

Balance Sheet

Concept 2020 Q3 2019 Q3 2019 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $36.10M $38.06M $42.40M
YoY Change -5.16% -31.98% -34.06%
Cash & Equivalents $18.15M $17.34M $14.51M
Short-Term Investments $18.00M $20.72M $27.89M
Other Short-Term Assets $1.800M $1.100M $1.500M
YoY Change 63.64% -35.29% -11.76%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $38.20M $39.14M $43.87M
YoY Change -2.41% -32.09% -33.53%
LONG-TERM ASSETS
Property, Plant & Equipment $3.300M $1.386M $1.512M
YoY Change 138.1% -30.7% -31.27%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $100.0K $221.0K $215.0K
YoY Change -54.75% 121.0% 115.0%
Total Long-Term Assets $3.400M $4.601M $4.891M
YoY Change -26.1% 113.5% 112.65%
TOTAL ASSETS
Total Short-Term Assets $38.20M $39.14M $43.87M
Total Long-Term Assets $3.400M $4.601M $4.891M
Total Assets $41.60M $43.75M $48.76M
YoY Change -4.9% -26.85% -28.61%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.400M $1.324M $664.0K
YoY Change 5.74% 120.67% -17.0%
Accrued Expenses $3.600M $1.579M $1.582M
YoY Change 127.99% -34.21% -36.72%
Deferred Revenue $352.0K $536.0K
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $3.100M $7.844M $7.817M
YoY Change -60.48% 1.87% 1.52%
Total Short-Term Liabilities $8.000M $11.83M $11.30M
YoY Change -32.36% 10.54% 1.84%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $2.742M $4.600M
YoY Change -100.0% -72.85% -61.02%
Other Long-Term Liabilities $1.600M $2.400M $2.600M
YoY Change -33.33%
Total Long-Term Liabilities $1.600M $2.742M $4.600M
YoY Change -41.65% -72.85% -61.02%
TOTAL LIABILITIES
Total Short-Term Liabilities $8.000M $11.83M $11.30M
Total Long-Term Liabilities $1.600M $2.742M $4.600M
Total Liabilities $9.500M $14.57M $15.90M
YoY Change -34.8% -29.95% -30.55%
SHAREHOLDERS EQUITY
Retained Earnings -$316.3M -$310.7M
YoY Change 8.19%
Common Stock $50.00K $49.00K
YoY Change 66.67%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $32.20M $26.74M $30.23M
YoY Change
Total Liabilities & Shareholders Equity $41.60M $43.75M $48.76M
YoY Change -4.9% -26.82% -28.61%

Cashflow Statement

Concept 2020 Q3 2019 Q3 2019 Q2
OPERATING ACTIVITIES
Net Income -$6.599M -$5.645M -$5.848M
YoY Change 16.9% -20.65% -43.83%
Depreciation, Depletion And Amortization $130.0K $160.0K $150.0K
YoY Change -18.75% -15.79% -25.0%
Cash From Operating Activities -$5.550M -$4.260M -$4.820M
YoY Change 30.28% -34.06% -47.49%
INVESTING ACTIVITIES
Capital Expenditures -$10.00K -$30.00K $0.00
YoY Change -66.67% -25.0% -100.0%
Acquisitions
YoY Change
Other Investing Activities $1.750M $7.230M $2.300M
YoY Change -75.8% -65.17% -68.14%
Cash From Investing Activities $1.740M $7.210M $2.300M
YoY Change -75.87% -65.22% -67.92%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 330.0K -120.0K 4.070M
YoY Change -375.0% -94.0% -735.94%
NET CHANGE
Cash From Operating Activities -5.550M -4.260M -4.820M
Cash From Investing Activities 1.740M 7.210M 2.300M
Cash From Financing Activities 330.0K -120.0K 4.070M
Net Change In Cash -3.480M 2.830M 1.550M
YoY Change -222.97% -76.94% -158.49%
FREE CASH FLOW
Cash From Operating Activities -$5.550M -$4.260M -$4.820M
Capital Expenditures -$10.00K -$30.00K $0.00
Free Cash Flow -$5.540M -$4.230M -$4.820M
YoY Change 30.97% -34.11% -47.21%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2044000
CY2020Q3 us-gaap Operating Expenses
OperatingExpenses
6660000
CY2020Q1 us-gaap Profit Loss
ProfitLoss
1752000
CY2020Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
148000
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4616000
CY2020Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1605000
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-6512000
CY2020Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-88000
CY2020Q3 us-gaap Profit Loss
ProfitLoss
-6600000
CY2020Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-1000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-6599000
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.68
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
9648534
CY2019Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
8000
CY2019Q2 life Stock Issued During Period Value At The Market Offerings Net Of Offering Costs
StockIssuedDuringPeriodValueAtTheMarketOfferingsNetOfOfferingCosts
1146000
CY2019Q2 life Stock Issued During Period Value At Registered Direct Offering
StockIssuedDuringPeriodValueAtRegisteredDirectOffering
4918000
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
509000
CY2019Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
8000
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-5848000
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
30226000
CY2020Q1 life Issuance Of Common Stock From Underwritten Follow On Offering Net Of Offering Costs
IssuanceOfCommonStockFromUnderwrittenFollowOnOfferingNetOfOfferingCosts
18779000
CY2020Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
41967000
CY2020Q3 life Stock Issued During Period Value At The Market Offerings Net Of Offering Costs
StockIssuedDuringPeriodValueAtTheMarketOfferingsNetOfOfferingCosts
2334000
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
324000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
33650000
CY2019Q1 life Stock Issued During Period Value At The Market Offerings Net Of Offering Costs
StockIssuedDuringPeriodValueAtTheMarketOfferingsNetOfOfferingCosts
1381000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-6137000
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
29485000
CY2019Q3 life Stock Issued During Period Value At Registered Direct Offering
StockIssuedDuringPeriodValueAtRegisteredDirectOffering
1878000
CY2019Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
278000
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
26736000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
441000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
478000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1125000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1358000
us-gaap Accretion Expense
AccretionExpense
324000
us-gaap Accretion Expense
AccretionExpense
556000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-55000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
245000
life Operating Lease Right Of Use Asset Amortization
OperatingLeaseRightOfUseAssetAmortization
579000
life Operating Lease Right Of Use Asset Amortization
OperatingLeaseRightOfUseAssetAmortization
536000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-10000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
28000
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
145000
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-101000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1146000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
92000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
862000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-159000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-155000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
352000
life Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-555000
life Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-324000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9900000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-15097000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
197000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
38000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
20168000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
34668000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
24050000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
40800000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
12000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
51000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
3697000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
6145000
life Proceeds From Issuance Of Common Stock Under Employee Stock Purchase Plan
ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan
6000
life Proceeds From Issuance Of Common Stock Under Employee Stock Purchase Plan
ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan
8000
life Proceeds From Issuance Of Common Stock Through At Market Offering Net Of Offering Costs
ProceedsFromIssuanceOfCommonStockThroughAtMarketOfferingNetOfOfferingCosts
2359000
life Proceeds From Issuance Of Common Stock Through At Market Offering Net Of Offering Costs
ProceedsFromIssuanceOfCommonStockThroughAtMarketOfferingNetOfOfferingCosts
4405000
life Proceeds From Issuance Of Common Stock Through Registered Direct Offering Net Of Offering Costs
ProceedsFromIssuanceOfCommonStockThroughRegisteredDirectOfferingNetOfOfferingCosts
4918000
life Proceeds From Issuance Of Common Stock Through Underwritten Follow On Offering Net Of Offering Costs
ProceedsFromIssuanceOfCommonStockThroughUnderwrittenFollowOnOfferingNetOfOfferingCosts
18779000
us-gaap Repayments Of Debt
RepaymentsOfDebt
6000000
us-gaap Repayments Of Debt
RepaymentsOfDebt
6000000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
15144000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3331000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
8941000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-5621000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
9210000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
22962000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
18151000
CY2019Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
17341000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1031000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1062000
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-align:justify;margin-bottom:6pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our condensed consolidated financial statements are prepared in accordance with GAAP. The preparation of our condensed consolidated financial statements requires us to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in our condensed consolidated financial statements and accompanying notes. The most significant estimates in our condensed consolidated financial statements relate to the clinical trials and research and development expenses. Although these estimates are based on our knowledge of current events and actions we may undertake in the future, actual results may ultimately differ materially from these estimates and assumptions. Though the impact of the COVID-19 pandemic to our business and operating results presents additional uncertainty, we continue to use the best information available to us in our critical accounting estimates.</p>
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Reclassifications</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain reclassifications have been made to prior year amounts to conform to the current year presentation. The reclassifications were not material to the condensed consolidated financial statements.</p>
CY2020Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
17987000
CY2020Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
8000
CY2020Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
17995000
CY2019Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
21924000
CY2019Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
10000
CY2020Q3 life Cash And Cash Equivalents And Available For Sale Investments
CashAndCashEquivalentsAndAvailableForSaleInvestments
36100000
CY2020Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
598266
CY2019Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1469689
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1469689
us-gaap Debt Instrument Payment Terms
DebtInstrumentPaymentTerms
Issuable in three separate tranches (the Term Loans), $10.0 million of which was funded in November 2016, $5.0 million of which was funded in June 2017 and $5.0 million of which was funded in December 2017.
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
254000
CY2019Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
21934000
CY2020Q1 life Upfront Payment Received
UpfrontPaymentReceived
8000000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
404000
CY2020Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
312000
CY2020Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
2439000
CY2020Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
200000
CY2019Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
200000
us-gaap Operating Lease Cost
OperatingLeaseCost
700000
us-gaap Operating Lease Cost
OperatingLeaseCost
700000
CY2020Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y8M12D
CY2020Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.096
CY2020Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
1056695
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
351078
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
410032
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
186205
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
574905
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
51.34
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
4.19
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
33.83
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
23.39
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
324000
CY2019Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
278000

Files In Submission

Name View Source Status
0001564590-20-053928-index-headers.html Edgar Link pending
0001564590-20-053928-index.html Edgar Link pending
0001564590-20-053928.txt Edgar Link pending
0001564590-20-053928-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
gmv3rgly4cri000001.jpg Edgar Link pending
life-10q_20200930.htm Edgar Link pending
life-20200930.xml Edgar Link completed
life-20200930.xsd Edgar Link pending
life-20200930_cal.xml Edgar Link unprocessable
life-20200930_def.xml Edgar Link unprocessable
life-20200930_lab.xml Edgar Link unprocessable
life-20200930_pre.xml Edgar Link unprocessable
life-ex101_245.htm Edgar Link pending
life-ex311_8.htm Edgar Link pending
life-ex312_6.htm Edgar Link pending
life-ex321_7.htm Edgar Link pending
life-ex322_9.htm Edgar Link pending
life-ex51_184.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending